



DECODING MENTAL HEALTH


Digital Precision
Medicine for
Mental Health



Mental illness will be the **leading cause of disability** by 2030¹ costing **\$6 Trillion**

1 out of 4 of us will experience a **mental disorder**¹

>45% of patients with chronic conditions struggle with **behavioral health**²




PROBLEM

No objective
monitoring
for mental health



Feel's proprietary
**Digital Precision
Medicine Platform**
brings continuous
and passive
monitoring to
mental health.



SOLUTION | LINKING REMOTE MONITORING WITH PRECISE INTERVENTION 24/7/365



IMPACT TO PATIENTS ACROSS MENTAL HEALTH CONDITIONS




23 Research & clinical studies



Active 2018-2024

6 THERAPEUTIC AREAS IN CNS

6 TAs PIPELINE
(e.g. Oncology, Hematology et al.)



MDD

Countries: 5 Subjects: 817

GAD

Countries: 5 Subjects: 427

PTSD

Countries: 1 Subjects: 95

Healthy w/ risk factors

Countries: 5 Subjects: 1154

ADHD

Countries: 1 Subjects: 100

Eating Disorders

Countries: 1 Subjects: 80

MS*

Countries: 1 Subjects: 50

Total countries Total Patients

9

2,727



PUBLICATIONS



**Outcomes of Feel
DTx for
Depression and
Anxiety**

Precision DTx
delivers superior
improvement in
outcomes in
depression and/or
anxiety

[Read Publication](#)



**Precision and
accuracy of
emotional state
detection and
recognition**

87% precision in
detecting
changes in the
mood state of
patients in
psychiatry

[Read Publication](#)



**Psychophysiological
index for
Stress Resilience**

Psychophysiological
index for
Stress strongly
correlates with
changes in
Cortisol levels

[Read Publication](#)



**Psychophysiological
index for
Stress**

Electrodermal
Activity (EDA)
can be a stress
resilience metric
in stressful
conditions

[Read Publication](#)



**Psychophysiological
index for
Stress**

Psychophysiological
index for
Stress strongly
correlates with
changes in the
Endocannabinoid
System

[Read Publication](#)



**Outcomes of Feel
DTx for ADHD**

Precision DTx
shows
improvement in
mental health
outcomes for
ADHD
populations

[Read Publication](#)



**Digital Biomarker
for Detection of
ADHD**

Detection of
ADHD utilizing
physiological
signals from
wearables

Publication
Pending

PATENTS



Emotion Detection

Patent for
detecting
changes in the
mood state of an
individual based
on physiological &
digital data

Patent No:
US1141068282



Emotion Detection 2

Method for
detecting and
recognizing an
emotional state
of a user
(Continuation)

Patent Granted



ADHD Digital Biomarker

Method for
characterizing,
detecting, and
monitoring ADHD

Patent pending



Insomnia Digital Biomarker

System and
method for
characterizing,
detecting, and
monitoring
insomnia

Patent pending



Depression Relapse Digital Biomarker

System and
method for
characterizing,
detecting, and
monitoring
relapse in
depression

Patent pending

LEADERSHIP TEAM



GEORGE ALEXOPOULOS
CO-FOUNDER & CEO
FORMER MCKINSEY,
COLUMBIA



HARRIS TSIRBAS, PhD
CO-FOUNDER & CTO
PHD IN BIOMEDICAL
ENGINEERING



SHARON KAPLOW
VP OF CLINICAL
OPERATIONS,
FORMER CLINICAL
LEAD AbleTo

INDUSTRY EXPERTS



MICHEL YOUNATSOS
FORMER CEO OF
BIOGEN



STAYCE BECK
FORMER DIRECTOR
PERSONALIZED
MEDICINE &
BIOMARKERS @ FDA



TORSTEN OLETZKY
FORMER CEO OF
ERGO

PSYCHIATRY EXPERTS



DR. NIKOS DASKALAKIS
PROFESSOR OF
PSYCHIATRY AT
HARVARD



DR. PETER YELLOWLEES
PROFESSOR OF
PSYCHIATRY AT
UC DAVIS



DR. JOAQUIN ANGUERA
PROFESSOR OF
PSYCHIATRY AT
UCSF

INVESTORS



Felicis

SATORI
CAPITAL

SUSV



arthemis

A COMPANY OF:
JLABS
Johnson & Johnson

CORE TEAM

31

TEAM MEMBERS
IN THE USA & EUROPE

\$180k

CORE GROSS
MONTHLY BURN RATE

9

POST-DOCS
IN THE CORE TEAM

4

PROFESSORS OF
PSYCHIATRY

800+

TEAM MEMBER
PUBLICATIONS

16000+

TEAM MEMBER
CITATIONS

PRE-SERIES A FUNDRAISING


\$1M left in a
\$3.5M round to
reach an
inflection point

EXISTING ROUND

- Closed \$2.5M led by expert Neurotech investors (Satori Neuro)

SATORI  CAPITAL

METAVALLON



Terms: Convertible Note with \$30M Cap and 20% Discount

MILESTONES

- FDA approval of our wearable as a 510k class II medical device

Empatica closed their series B financing from Sanofi after receiving FDA clearance for a similar device



- Launch as a Drug+ in the market & clearance of Feel DTx program as an adjunct to medication

Recent FDA clearance of DTx for the Adjunctive Treatment of MDD





George Eleftheriou, Co-Founder & CEO
479 Jessie Street, San Francisco, CA 94103

+1 551 232 1020 | george@feeltherapeutics.com | www.feeltherapeutics.com